Programme
Schedule at a glance
Click here to download the schedule at a glance
Thursday, 1 July 2010
12:00 - 13:30 | PFIZER SATELLITE SYMPOSIUM - Room: 251
Early detection and diagnosis of psoriatic arthritis: The importance of multi-disciplinary management
12:00 | Chairman’s welcome and introduction - Professor Hervé Bachelez
12:05 | Detection of psoriatic arthritis - Professor Torello Lotti
12:25 | The importance of early diagnosis in psoriatic arthritis - Dr Diamant Thaçi
12:40 | Practical treatment options for psoriatic arthritis - Dr Frank Behrens
12:55 | Managing patients in shared care - Dr Frank Behrens and Dr Diamant Thaçi
13:15 | Question and answer session - All
13:25 | Concluding remarks and close - Professor Hervé Bachelez
14 :00 - 15:30 | Plenary Session I - Treating special manifestations - Room: Amphitheatre Bleu
Chairs: Louis Dubertret (France), Peter Van de Kerkhof (The Netherlands)
14:00 - o 001 Treating psoriasis of the nails - Robert Baran (France)
14:18 - o 002 Treating psoriasis of the scalp/treating intertriginous psoriasis
Gottfried Wozel (Germany)
14:36 - o 003 Treating pustular psoriasis - Peter Van de Kerkhof (The Netherlands)
14:54 - o 004 Treating erythrodermic and flaring psoriasis - Carlos Ferrandiz (Spain)
15:12 - o 005 Psoriasis in black African people - Fatimata Ly (Sénégal)
16:00 - 17:30 | Workshop 1a - Psoriasis and Children - Room: 252
Chairs: Christine Bodemer (France), Arnold P. Oranje (The Netherlands)
16:00 - o 006 General pattern presentation of psoriasis in childhood and epidemiology
Michel De la Brassine (Belgium)16:15 - o 007 Which topic treatments are licensed and can be used?
Arnold P. Oranje (The Netherlands)16:30 - o 008 Which systemic treatments can be recommended for children?
Amrinder Jit Kanwar (India)16:45 - o 009 Is there enough experience to use TNF-alpha antagonists in children?
Christine Bodemer (France)17:00 - o 010 Photo and photochemotherapy in children - Erhard Hölzle (Germany)
17:15 - P 001Outpatient visits by children with psoriasis in the united states: 1979 TO 2007
S. Vogel*, B. Yentzer, A. Fleischer Jr., S. Feldman, K. Cordoro (United States)17:20 - P 002Clinical experience with systemic cyclosporine a treatment in severe childhood psoriasis
E. Bulbul Baskan*, S. Yazici, S. Tunali, H. Saricaoglu (Turkey)
16:00 - 17:30 | Workshop 1b - Psoriasis during pregnancy and lactation - Room: 251
Chairs: Esteban Dauden (Spain), Alexa Kimball (USA)
16:00 - o 011Influence of psoriasis on pregnancy/lactation and vice versa - Diego de Argila (Spain)
16:12 - o 012Topical therapy and pregnancy/lactation - Luis Puig (Spain)
16:24 - o 013Phototherapy and pregnancy/lactation - José Manuel Carrascosa (Spain)
16:36 - o 014Conventional systemic therapy and pregnancy/lactation - Sophie Weatherhead (UK)
16:48 - o 015Biologic therapy and pregnancy/lactation - Alexa Kimball (USA)
16:30 - 17:30 | Workshop 1c - Systemic therapies: adverse events and contraindications - Room: Amphitheatre Bleu
Chairs: Sergio Chimenti (Italy), Thomas Luger (Germany)
16:00 - o 016Acitretin and Systemic Retinoids - Peter Van de Kerkhof (The Netherlands)
16:15 - o 017Methotrexate - Richard Warren (UK)
16:30 - o 018FAE’s - Wolfram Sterry (Germany)
16:45 - o 017Ciclosporine - Maria Esposito (Italy)
17:00 - o 019TNF-inhibitors, Infliximab, Adalimumab, Etanercept - Marina Papoutsaki (Italy)
17:15 - o 020Ustekinumab - Thomas Luger (Germany)
Friday, 2 July 2010
08:30 - 10:00 | Workshop 2a - Psoriasis Arthritis + Imaging - Room: Amphitheatre Bleu
Chairs: Jonathan Barker (UK), Bruce Kirkham (UK)
08:30 - o 022Imaging nails to define the link between psoriatic arthritis and psoriasis
Dennis McGonagle (UK)08:45 - o 023Role of MRI in defining psoriatic arthritis severity - Ai Lyn Tan (UK)
09:00 - o 024Methods of imaging in psoriatic arthritis - Mikkel Ostergaard (Denmark)
09:15 - o 025Advances in classification of psoriatic arthritis and implications for treatment
Bruce Kirkham (UK)09:30 - P 003Fatigue in psoriatic arthritis: correlation between disease activity and various scales
(FACIT, PDI, HAQ, BASDAI AND HAD)
S. Carneiro*, C. Carneiro, M. Chaves, A. P. Frade, A. Drummond, M. Ramos-e-Silva,
E. Albuquerque (Brazil)09:35 - P 004Psoriasis: correlation between joint and ungal involvement, extension and duration of
cutaneous disease and quality of life
S. Carneiro*, S. Bezerra, C. Carneiro, G. Verardino, M. Ramos-e-Silva (Brazil)
08:30 - 10:00 | Workshop 2b - Triggers for Psoriasis - Room: 251
Chairs: Jörg Prinz (Germany), Luigi Naldi (Italy)
08:30 - o 026The role of streptococci in psoriasis: Pathogenic mechanisms - Jörg Prinz (Germany)
08:45 - o 027Psoriasis and the tonsils - clinical examinations and laboratory findings:
A rationale for tonsillectomy?
Helgi Valdimarsson (Iceland)09:00 - o 028Environmental and lifestyle triggers of psoriasis - Luigi Naldi (Italy)
09:15 - o 029Pharmacologic triggers of psoriasis: Mechanisms and practical consequences
Tamar Njisten (The Netherlands)09:30 - P 005Alcohol and its metabolites acetaldehyde and acetone as trigger factors for psoriasis
Á. Farkas*, L. Kemény (Hungary)09:35 - P 006Surrogate cardiovascular risk factors in psoriasis patients - I. Grozdev*, L. Cao, D. Kast, M. Rodriguez, E. Kern, T. McCormick, K. Cooper, N. Korman (United States)
08:30 - 10:00 | Workshop 2c - Optimizing systemic treatments / Combining different systemic therapies -Room: 252
Chairs: Hervé Bachelez (France), Sandra Philipp (Germany)
08:30 - o 030Combination of MTX and Biologics, does it reduce antibody production,
should it be the standard of care? Hervé Bachelez (France)08:45 - o 031Combinations and rotation of conventional systemic treatments: Is it worth it?
Luis Puig (Spain)09:00 - o 032Fumaric Acid Esters, Combination with other systemic therapies -
Sandra Philipp (Germany)09:15 - o 033Impact of treatments of psoriatic arthritis on skin psoriasis - Michael Sticherling
09:15 - P 007Efficacy and safety of fumaric acid ester for the treatment of psoriasis in patients with co-morbidities and co-medication - D. Thaci* (Germany)
10:30 - 12:00 | Plenary Session II - Systemic treatments - Room: Amphitheatre Bleu
Chairs: Carle Paul (France), Enno Christophers (Germany)
10:30 - o 034Traditional systemic treatments - Louis Dubertret (France)
10:52 - o 035Approved biologic treatments - Wolfram Sterry (Germany)
11:14 - o 036What is in the pipeline - Alan Menter (USA)
11:36 - o 037Dilemmas in understanding psoriasis phenotypes - Enno Christophers (Germany)
12:00 - 14:00 | Meeting of the national coordinators of the Psoriasis International Network- Room : 243
12:30 - 14:00 | JANSSEN-CILAG SATELLITE SYMPOSIUM - Room 252
Biologics for moderate-to-severe plaque psoriasis - clinical and practical considerations
Prof. Wolfram Sterry, Charité Universitätsmedizin, Berlin, Germany
Prof. Hervé Bachelez, Saint-Louis University Hospital, Paris, France
12:30-12:35 | Welcome - Wolfram Sterry
12:35-13:00 | The immunological basis and efficacy of biologic therapy in psoriasis - Hervé Bachelez
13:00-13:25 | Pharmacokinetics and the tolerability profiles of biologics therapies - Wolfram Sterry
13:25-13:55 | Biologic therapy in the clinic: practical considerations Esteban Daudén, Robert Gniadecki
13:55-14:00 | Closing remarks - Wolfram Sterry
14:00 - 15:30 | Workshop 3a – Phototherapy - Room: 251
Chairs: Lajos Kemeny (Hungary), Thomas Schwarz (Germany)
14:00 - o 038From heliotherapy to NB-UVB - Arnon Cohen (Israel)
14:15 - o 039Efficacy - What is the evidence? - Carle Paul (France)
14:30 - o 040Combining phototherapy with systemic therapies - Herbert Hönigsmann (Austria)
14:45 - o 041Lasertherapy - Lajos Kemeny (Hungary)
15:00 - o 042Skin cancer from UV - and PUVA therapy, what is the actual risk? - Adrian Tanew (Austria)
14:00 - 15:30 | Workshop 3b - Topical therapies - Room: 252
Chairs: Harald Gollnick (Germany), Knud Kragballe (Denmark)
14:00 - o 043How to use corticosteroids for longterm therapy? - Peter van de Kerkhof (The Netherlands)
14:15 - o 044Comparative efficacy and tolerability of vitamin D analogues - Siegfried Segaert (Belgium)
14:30 - o 045Calcineurin inhibitors – Their role in the management of psoriasis
Diamant Thaci (Germany)14:45 - o 046Is there a place for retinoids, tar and dithranol? - Harald Gollnick (Germany)
15:00 - o 047Topicals in the pipeline - Knud Kragballe (Denmark)
14:00 - 15:30 | Workshop 3c – Pathophysiology - Room: Amphitheatre Bleu
Chairs: Frank Nestle (UK), Georg Stingl (Austria)
14:00 - o 048From gene to function in psoriasis - Frank Nestle (UK)
14:22 - o 050Cellular source of TNF producing cells in psoriasis - Georg Stingl (Austria)
14:45 - o 051Biomarkers in psoriasis - Wolf-Henning Boehncke (Germany)
15:00 - P 008Role of il-21 in pathogenesis of psoriasis - A. Costanzo*, E. Botti, R. Caruso, F. Pallone, S. Chimenti, G. Monteleone (Italy)
15:05 - P 009Topo-proteome analysis of psoriasis under infliximab treatment revealing crucial involvement of, both, cd4- and cd8-positive cd45r0-t-cells in the resolution of the psoriatic plaque -
B. Bonnekoh*, R. Böckelmann, H. Hofmeister, A. Pommer, H. Gollnick (Germany)15:00 - P 010TNF-Alpha indirectly contributes to the epidermal alterations in psoriasis by amplifying the effects of the T-cells cytokine IL-22 - E. Witte*, K. Wolk, K. Witte, K. Warszawska, H. Volk, W. Sterry, R. Sabat (Germany)
15:05 - P 011Interleukin(IL)-22, a T-cell mediator, induces in keratinocytes il-20, a tissue cell mediator - Wolf-Henning Boehncke (Germany)
15:05 - P 012The epidermal alterations in psoriasis are mediated by IL-22, but not by
other T-cell mediators including IL-17 or IFN-Gamma - K. Wolk*, E. Witte, H. Haugen, W. Xu, S. Kunz, K. Waggie, M. Anderson, E. v. Baur, K. Witte, K. Warszawska, S. Kirsch, S. Philipp, C. Johnson-Leger, W. Sterry, H. Volk, R. Sabat (Germany)
16:00 - 17:30 | Plenary Session III - Psoriasis & Comorbidities - Room: Amphitheatre Bleu
Chairs: Paolo Gisondi (Italy), Giampiero Girolomoni (Italy)
16:00 - o 052Cardio-metabolic comorbidities in patients with psoriasis - Paolo Gisondi (Italy)
16:22 - o 053Psoriasis and the cardiovascular system - Wolf-Henning Boehncke (Germany)
16:40 - o 054Comorbidities: Consequences for practical treatment, screening for risk factors, indication
for early initiation of systemic treatments? - Alexa Kimball (USA)17:06 - o 055Insulin resistance in psoriasis: Influence of anti-TNF a treatment
Robert Gniadecki (Denmark)
Saturday, 3 July 2010
08:30 - 10:00 | Workshop 4a - Treatment of Psoriasis during infections - Room: 252
Chairs: Margrit Simon (Germany), Diamant Thaci (Germany)
08:30 - o 056Treatment of a patient with psoriasis and HIV - Case report - Kirsten Leuow (Greece)
08:45 - o 057Viral infections and psoriasis - Case report - Michael Sticherling (Germany)
09:00 - o 058Treatment of bacterial infection in patients undergoing systemic treatment
Diamant Thaci (Germany)09:15 - o 059Treatment of patients with Hepatitis C - Margrit Simon (Germany)
09:30 - P 013Biologic treatments for psoriasis in patients with hepatitis C virus infection and other liver diseases: experience in 29 patients - E. Vilarrasa*, L. Puig, A. Alomar (Spain)
08:30 - 10:00 | Workshop 4b - Psychological Aspects of Psoriasis - Room: 251
Chairs: Tsira Leonidze (Georgia), Eva Peters (Germany)
08:30 - o 060Neuroimmunological links in dermatology - Eva Peters (Germany)
08:45 - o 061The role of personal predisposition on the outcomes of psoriasis treatment
Tsira Leonidze (Georgia)09:00 - o 062The psychosoma of psoriasis - leads and lessons from the clinic - Uwe Gieler (Germany)
09:15 - o 063Altered stress-related immune changes in psoriasis - Ulrike Raap (Germany)
09:30 - P 014Depressive and negativistic cognitive styles increase illness-related strain in patients with psoriasis - J. Bahmer*, M. Kazén, N. Baumann, J. Kuhl (Germany)
09:35 - P 015Measurement of the parameters of quality of life in the patients with psoriasis
R. Keshileva* (Kazakhstan)09:40 - P 016Immunohistochemical analysis of inflammatory markers and neuropeptides in psoriasis -
E. Mozeika*, M. Pilmane, J. Kisis (Latvia)09:45 - P 017Psoriasis manifestations during the war - A. Gercari*, M. Ferizi (Serbia)
08:30 - 10.00 | Workshop 4c - Update of Psoriasis Registries - Room: Amphitheatre Bleu
Chairs: Matthias Augustin, Tony Omerod
08:30 - o 064Psoriasis Registries throughout Europe using the example of the UK -
Anthony Ormerod (UK)08:45 - o 065Psoriasis Registries throughout Latin America - Dario Kivelevitch (Argentina)
09:00 - o 066Psoriasis Registries throughout the USA - Alan Menter (USA)
09:15 - o 067Psoriasis Registries throughout Germany and Psonet Europe
Matthias Augustin (Germany)09:30 - P 018Evaluation of a three-dimensional patient self-assessment psoriasis severity index for use in routine clinical practice - R. Chalmers*, A. Menter (United Kingdom)
09:35 - P 019Genomewide association study (gwas) in psoriasis
L. Puig*, A. Julià, R. Tortosa, E. Fonseca, C. Ferrándiz, P. de Unamuno, J. L. Sánchez Carazo,
E. Daudén, D. Moreno, F. Vanaclocha, J. M. Hernanz, J. L. López, E. Herrera, S. Marsal (Spain) A. Gercari*, M. Ferizi (Serbia)
10:30 - 12:00 | Plenary Session IV - Difficult clinical cases open to discussion - Room: Amphitheatre Bleu
Chairs: Alan Menter (USA), Wolfram Sterr y (Germany), Georg Stingl (Austria)
Presentation of case reports
- How would you decide?
- Discussion of therapeutic decisions in difficult cases
- Ted System
12:00 - 14:00 | SCHERING PLOUGH SATELLITE SYMPOSIUM - Room: 252
Long-term Benefit-Risk: Interpreting the Evidence
12:30-12:35 | Welcome and Introductions
12:35-12:55 | Psoriasis as a Systemic Disease: Benefit-Risk Considerations
12:55-13:15 | Long-term Efficacy: What do We Really Know?
13:15-13:35 | Six Years of Infusion Therapy: What Have We Learned?
13:35-13:55 | Question-and-Answer Session
13:55-14:00 | Closing Remarks
Alan Menter, MD, PhD, Dallas, Texas, USA
Sergio Chimenti, MD, Rome, Italy
Kristian Reich, MD, Hamburg, Germany
14:00 - 15:30 | ABBOTT SATELLITE SYMPOSIUM - Room: 252
Advances in Psoriasis Management: Much Achieved; More to do? The Experts Debate
Chair: Professor Wolfram Sterry (Germany)
14:00 | Chair’s introduction - Professor Wolfram Sterry
14.05-14.30 | Debate 1: The key to effective psoriasis management, maximizing patients’ quality of life and preventing its progressive impairment, is early and tight disease control - Professor Alexa Kimball, Professor Carle Paul
• Panel and audience discussion
• Audience vote on the topic
14.30-14.55 | Debate 2: We now have the knowledge and tools to achieve sustained clearance for all psoriasis patients with acceptable benefit–risk - Professor Ken Gordon and Professor Kristian Reich
• Panel and audience discussion
• Audience vote on the topic
14.55-15.20 | Debate 3: Psoriasis management has reached a new level, providing optimal care for all psoriasis patients - Professor Kristian Reich, Professor Carle Paul
• Panel and audience discussion
• Audience vote on the topic
15.20-15.30 | Summary and conclusions - Professor Wolfram Sterry
16:00 - 17:35 | Workshop 5a - Guidelines, assistance for treating psoriasis - Room: 251
Chairs: Alexander Nast, Phyllis Spuls
16:00 - o 068Introduction on available guidelines - how to find them, how to use them - Phyllis Spuls
16:15 - o 069Overview of recommendations in psoriasis guidelines - Luigi Naldi
16:30 - o 070Practical information on specific situations - recommendations in the psoriasis guidelines
(liver biopsy? Dosage schemes? Monitoring? What is recommended in the guidelines? - Catherine Smith16:45 - o 071Treatment aspects not covered by the guidelines - Tamar Njisten
17:00 - o 072Evaluation of guidelines and guidelines in the future
(what will be next? Living guidelines, did the guidelines change the way we treat?) - Alexander Nast17:15 - P 020 Relationship between methotrexate dosing and clinical response: subanalysis of the champion study of psoriasis - J. Saurat*, K. Unnebrink, E. Sasso, W. Kampman (Switzerland)
17:20 - P 021 Transitioning psoriasis patients to adalimumab following a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study - B. Strober*, Y. Poulin, F. Kerdel, R. Langley, A. Menter, K. Papp, Y. Gu, M. Okun (United States)
17:25 - P 022 Efficacy and safety of weekly adalimumab in psoriasis patients with a less than pasi 50 response to 40 mg every other week: results from an open-label extension study - C. Leonardi*, A. Menter, Y. Gu, M. Okun (United States)
17:30 - P 023 ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis: efficacy and safety results - B. Strober*, J. Crowley, P. Yamauchi, S. Yoo, Y. Gu, J. Valdes (United States)
16:00 - 17:30 | Workshop 5b - How to use... - Room: 252
Chairs: Sergio Chimenti (Italy), Annamari Ranki (Finland)
16:00 - o 073MTX (new insights, prokollagen III peptid, etc., liver biopsies-current recommendations)
Robert Chalmers (UK)16:15 - o 074Retinoids - (lipids, teratogenicity) - Frederik G. Larsen (Denmark)
16:30 - o 075Fumaric acid esters: (eg. Lymphocytopenia) - Wolfram Sterry (Germany)
16:45 - o 076Ciclosporin (eg. Nephrotoxicity) - Sergio Chimenti (Italy)
17:25 - P 024 Comparative study of oral acitretin and oral methotrexate in the treatment of palmoplantar psoriasis - T. Rao*, S. Babu (India)
17:30 - P 025Characterization of psoriasis patients treated in the outpatient department of a university hospital in germany- S. Philipp*, F. Bachmann, G. Kokolakis, R. Sabat, W. Sterry (Germany)
16:00 - 17:30 | Workshop 5c – Non conventional treatments in dermatology - Room: 253
Chair: Enno Christophers
16:00 - o 077Non-conventional treatments in Dermatology - Enno Christophers (Germany)
16:15 - o 078Dermatologist´s view on alternative therapies - Rudolf Happle (Germany)
16:30 - o 079Alternative therapies in psoriasis - Paolo Pigatto (Italy)
16:45 - P 026New insights of rifampicin in psoriasis
I. Grozdev*, J. Kazandjieva, N. Tsankov (Bulgaria)
16:00 - 17:40 | Workshop 5d – Psoriasis management in different parts of the world
(Drugs available, patient-doctor relationships, strategies of treatment...) - Room: Amphitheatre Bleu
Chairs: Edgardo Chouela (Argentina), Louis Dubertret (France)
16:00 - o 080Management of psoriasis in China - Min Zheng (China)
16:15 - o 081Management of psoriasis in South America - Edgardo Chouela (Argentina)
16:30 - o 082Management of psoriasis in India - Jayakar Thomas (India)
16:45 - o 083Management of psoriasis in North-African countries - Nejib Doss (Tunisia)
17:00 - o 084Management of psoriasis in Japan - Hajime Iizuka (Japan)
17:15 - P 027Study of incidence and heritability of psoriasis and benign migratory glossitis in a population of the state of são paulo, brazil
H. Gonzaga*, M. Jorge, J. Tomimori, C. Barbosa (Brazil)
17:20 - P 028Co-morbidities associated with psoriasis: an experience from middle east
N. Al-Mutairi* (Kuwait)
17:25 - P 029 Prevalence of metabolic syndrome and non alcoholic fatty liver disease in south indian psoriatic patients: a hospital based case - control study - S. Madanagobalane*, S. Anandan (India)
17:30 - P 030 Cost-of-illness in psoriasis: comparing inpatient and outpatient therapy from an economic point of view - S. Lang*, W. Peitsch, A. Ludwig, S. Goerdt, M. Goebeler (Germany)
17:35 - P 031 Clinical profile of psoriasis in yemen, a 4 years retrospective study of 241 patients
M. Alshami* (Yemen)
Sunday, 4 July 2010
9:00 - 12:00 | The Patients Organisation's meeting - Room: 253
Coordination: IFPA & EUROPSO
The Patients Organisations Meeting: Childhood psoriasis - a challenge for all
A clinical session organised by IFPA and EUROPSO
Following the theme of World Psoriasis Day 2010 “Childhood psoriasis – a challenge for all”, this meeting presented by IFPA and EUROPSO will focus on childhood and problems related to psoriasis and psoriatic arthritis in various age groups. Childhood patient cases from different parts of the world will be presented in this interactive meeting. Two patients representing the age group teenage will participate live and share their own experiences and history of living with psoriasis.
A panel of patient organisation leaders from the various IFPA regions will comment the cases and tell what the patient’s situation would be in their region in terms of access to treatment, costs of treatment, handling of the problem and other patient related questions including what kind of help and advice the patient could be offered by the patient organisation in that region of the world. The panel will be including representatives from Europe, Asia, Latin America, North America, Africa, and Australia.
Patients and doctors and anyone interested in these issues are warmly welcome to join and participate in the Patients Organisations Meeting.
13:00 - 17:00 | World Psoriasis Day Supporters Training Meeting - Room: 253
October 29 is World Psoriasis Day. An annual day dedicated to people with psoriasis and/or psoriatic arthritis. Conceived by patients for patients World Psoriasis Day is a global event, presented by IFPA, that gives an international voice to more than 125 million people around the world who suffers from psoriasis - many are children. The theme for World Psoriasis Day 2010 is “Childhood psoriasis - a challenge for all”
All IFPA Member Associations and other organizations and associations within the psoriasis field who celebrate and support World Psoriasis Day are invited and welcome to attend the meeting organized by IFPA. The purpose of the meeting is to educate and bring enthusiasm to all WPD Supporters in the work and planning of the national activities of WPD 2010. The global WPD Teddy bear campaign with the WPD International Drawing Competition for children from all over the world will be presented and introduced. The positive progress of IFPAs approach of WHO with the purpose of having psoriasis recognized as a serious, non communicable, systemic, inflammatory disease will be presented as well as the status and plans for the next steps in the ongoing global and national political actions and awareness raising activities to improve life for people living with psoriasis and psoriatic arthritis all over the globe.
Main topics
|
|
Posters
P 032 SERUM LEVELS OF IFN-Γ, TNF-Α, IL-1Β, IL-6, IL-8, AND IL-12
T. Y. Kim, C. C. Park, Y. B. Choe, J. I. Youn, H. J. Song (Republic of Korea)
P 033 PSORIASIS AND HEPATITIS C VIRUS
M. Matoshvili, A. Katsitadze, K. Berianidze, N. Jalaghania (Georgia)
P 034 ORAL LESIONS IN PSORIASIS: A CONTROLLED STUDY
R. Batra (India)
P 035 PSORIASIS IN CHILD IN OUR CLINIC
M. Ferizi (Serbia)
P 036 FIRST FEASIBILITY STUDY ON A PARTNERSHIP BETWEEN DERMATOLOGISTS AND PHARMACISTS FOR THE IMPROVEMENT OF PSORIASIS
MANAGEMENT
H. Barthelemy, M. Sigal, G. Chaby, M. Dordain, F. Maccari, R. Aubert, D. Sid-Mohand (France)
P 037 TREATMENT OF ACRODERMATITIS CONTINUA OF HALLOPEAU WITH USTEKINUMAB
F. Allegue, J. Pardo, J. Ruffin, E. Abbad, A. Lopez-Avila, J. Pereda, J. Garcia Solano (Spain)
P 038 A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF USTEKINUMAB IN JAPANESE PATIENTS WITH MODERATE TO SEVERE
PLAQUE PSORIASIS
A. Igarashi, T. Kato, M. Kato, H. Nakagawa (Japan)
P 039 USTEKINUMAB IMPROVES QUALITY OF LIFE IN JAPANESE PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
H. Nakagawa, T. Kato, M. Kato, A. Igarashi (Japan)
P 040 USTEKINUMAB DEMONSTRATES RAPID ONSET OF EFFICACY IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS
P. Rich, S. Feldman, R. Vender, J. Ortonne, M. Rustin, R. Kunynetz, N. Yeilding, S. Fakharzadeh, S. Li, J. Prinz and PHOENIX 1 and PHOENIX 2
Investigators (United States)
P 041 OLD DRUGS IN NEW REGIMEN FOR PSORIASIS TREATMENT
N. Tsiskarishvili, N. Tsiskarishvili (Georgia)
P 042 ERGOCALCIFEROL AND DAIVONEX IN COMPLEX TREATMENT OF PSORIASIS
N. Tsiskarishvili, T. Tsiskarishvili (Georgia)
P 043 USE OF ADALIMUMAB, A FULLY-HUMAN MONOCLONAL ANTI-TNF-ALPHA ANTIBODY, FOR LONG-TERM TREATMENT OF JAPANESE
PATIENTS WITH PLAQUE-TYPE PSORIASIS
H. Nakagawa and Japanese Dermatology Study Group on Adalimumab (Japan)
P 044 EFFICACY OF USTEKINUMAB IS SUSTAINED THROUGH 3 YEARS OF TREATMENT FOR PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
MAINTAINED ON Q12 WEEK DOSING BASED ON BODY WEIGHT
A. Kimball, B. Goffe, R. Bissonnette, N. Yeilding, S. Li, S. Fakharzadeh, K. Papp and PHOENIX I Investigators (United States)
P 045 IMPROVED CLINICAL RESPONSE FOLLOWING A THIRD DOSE OF USTEKINUMAB IN PSORIASIS PATIENTS NOT ACHIEVING PASI75 AT
WEEK 16: RESULTS FROM THE PHOENIX 1 AND PHOENIX 2 TRIALS
J. Sobell, T. Hamilton, K. Reich, V. Ho, D. Toth, N. Yeilding, S. Li, S. Fakharzadeh, N. Korman and PHOENIX 1 and PHOENIX 2 Investigators
(United States)
P 046 SUSTAINED EFFICACY OF USTEKINUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN INITIAL RESPONDERS
CONTINUING WITH MAINTENANCE THERAPY THROUGH YEAR 3
K. Gordon, J. Lambert, D. Gratton, D. Baker, R. Matheson, N. Yeilding, S. Fakharzadeh, S. Li, L. Guenther and PHOENIX 1 Investigators (United States)
P 047 USTEKINUMAB SAFETY UPDATE: CUMULATIVE EXPERIENCE FROM LONGER TERM FOLLOW-UP OF PATIENTS TREATED IN THE
USTEKINUMAB PSORIASIS CLINICAL DEVELOPMENT PROGRAM
K. Gordon, C. Leonardi, C. Griffiths, P. Szapary, N. Yeilding, M. Hsu, N. Wasel, J. Prinz, K. Reich and PHOENIX 1, PHOENIX 2, and ACCEPT
Investigators (United States)
P 048 EFFECT OF USTEKINUMAB ON COMMONLY MEASURED LABORATORY PARAMETERS: THREE YEAR RESULTS FROM THE PHOENIX 1
CLINICAL TRIAL
R. Bissonnette, J. Lambert, N. Yeilding, P. Szapary, M. Hsu, E. Rizova, A. Menter and PHOENIX 1 Investigators (United States)
P 049 CHARACTERIZATION OF INFECTIONS ASSOCIATED WITH USTEKINUMAB IN MODERATE TO SEVERE PSORIASIS PATIENTS
C. Leonardi, L. Guenther, N. Wasel, N. Yeilding, P. Szapary, M. Hsu, R. Langley, K. Reich and PHOENIX 1 and PHOENIX 2 Investigators (United States)
P 050 EFFICACY,SAFETY AND HEALTH-RELATED QUALITY OF LIFE OF INFLIXIMAB THERAPY IN PLAQUE PSORIASIS PATIENTS PREVIOUSLY
TREATED WITH ETANERCEPT: ANALYSIS OF PSUNRISE
A. Gottlieb, R. Kalb, A. Blauvelt, M. Heffernan, H. Sofen, J. Wang, S. Calabro, U. Kerkmann, M. Chevrier and PSUNRISE Investigators (United States)
P 051 INFECTION RATES IN USTEKINUMAB-TREATED PSORIASIS PATIENTS: OBSERVATIONS WITH UP TO 3 YEARS OF FOLLOW-UP AND
COMPARISONS TO A LARGE HEALTH CARE CLAIMS DATABASE
K. Gordon, A. Menter, P. Szapary, N. Yeilding, M. Hsu, L. Guenther, S. Philipp, P. Van de Kerkhov, R. Langley and PHOENIX 1, PHOENIX 2, and ACCEPT
Investigators (United States)
P 052 EFFICACY AND SAFETY OF USTEKINUMAB FOR PSORIASIS VULGARIS IN GERMAN PATIENTS – A SUBANALYSIS OF THE PHOENIX 2 STUDY
K. Shakery, P. Weisenseel, T. Giesecke, P. Szapary, M. Hsu, K. Reich and PHOENIX 2 Investigators (United States)
P 053 OPTIMIZATION OF THE PROCEDURES OF INFLIXIMAB INFUSION THERAPY IN AN INPATIENT SETTING
L. Lausen, K. Frederiksen (Denmark)
P 054 MANAGEMENT OF SEVERE PSORIASIS THROUGH A SERIES OF HOSPITALIZED PATIENTS
M. Madiha and Zribi J, Marrekchi S, Elleuch N, Meziou TJ, Boudaya S, Turki H. (Tunisia)
P 055 IN PATIENT CLINIC ADMISSION OF PSORIASIS: WHAT ARE THE MOTIVES
J. Zribi and M. Mseddi, W. Abdlmaksoud, A. Masmoudi, W. Hariz, T.J. Meziou, S. Boudaya (Tunisia)
P 056 EFFICACY AND SAFETY OF ADALIMUMAB, EFALIZUMAB AND ETANERCEPT IN THE TREATMENT OF PLAQUE-PSORIASIS “IN DAILY
PRACTICE"
L. Richter, M. Marker, B. Monshi, S. Richter-Mueksch, K. Rappersberger (Austria)
P 057 MANAGEMENT OF PSORIASIS THROUGH CLIMATOTHERAPY AT THE DEAD SEA IN JORDAN
Z. Bisharat (Jordan)
P 058 LONG-TERM SAFETY OF ADALIMUMAB FOR PSORIASIS: AN ANALYSIS OF ALL ADALIMUMAB EXPOSURE IN ALL GLOBAL CLINICAL TRIALS
C. Leonardi, K. Papp, A. Asahina, Y. Gu, S. Rozzo (United States)
P 059 THERAPEUTIC EFFICACY IN PSORIASIS: RESULTS OF A MULTICENTRIC STUDY
S. Youssef, K. Jaber, A. Khaled, M. Zghal, M. Denguezli, J. Meziou, M. R. Dhaoui, M. R. Kamoun, I. Mokhtar, R. Nouira, H. Turki, N. Doss (Tunisia)
P 060 MANAGEMENT OF RECALCITRANT PSORIASIS WITH TNF ANTAGONISTS: A TUNISIAN EXPERIENCE
H. Hammami, R. Benmously, T. Badri, S. Kochbati, M. Zghal, S. Fenniche, I. Mokhtar (Tunisia)
Posters
P 061 CUTANEOUS REACTIONS IN BIOLOGICAL TREATMENTS
M. Garcia-Bustinduy, S. Gonzalez-Hernandez, C. Rodriguez Garcia, N. Merino de Paz, P. Contreras Ferrer, M. Saez Rodriguez, M. Rodriguez Martin,
A. Noda Cabrera (Spain)
P 062 EFFICACY AND SAFETY OF ADALIMUMAB IN PATIENTS WITH PSORIASIS TREATED CONTINUOUSLY FOR OVER 3 YEARS
K. Gordon , Y. Poulin, Y. Gu, E. Sasso (United States)
P 063 UNUSUAL SIDE EFFECT TO METHOTREXATE IN PSORIASIS
K. Seetharam (India)
P 064 OUR EXPERIENCES USING ADALIMUMAB IN A PSORIASIS UNIT
J. Vilar, L. Dehesa, P. Valerón, N. Santana, G. Carretero (Spain)
P 065 PULSED DYE LASER: IS IT A HOPEFUL THERAPEUTIC OPTION FOR CHRONIC PSORIATIC PLAQUES?
M. Kheiralla, O. Azzam, A. El Tawdy, M. Fawzi (Egypt)
P 066 ROLE OF 1% COAL TAR IN CHRONIC PLAQUE PSORIASIS
V. Purohit (India)
P 067 SERIOUS INFECTIONS IN GLOBAL CLINICAL TRIALS OF ADALIMUMAB IN MODERATE TO SEVERE PSORIASIS
R. Langley, B. Strober, K. Reich, A. Asahina, Y. Gu, S. Rozzo (United States)
P 068 EFFICACY AND SAFETY RESULTS FROM A PHASE III, RANDOMIZED CONTROLLED TRIAL COMPARING TWO DOSING REGIMENS OF ABT-874
TO PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
K. Gordon, R. Langley, A. Gottlieb, K. Papp, A. Menter, G. Krueger, B. Strober, Y. Gu, J. Valdes (United States)
P 069 PRIVATE OFFICES AND PUBLIC HOSPITALS DEPARTMENTS OF DERMATOLOGY IN FRANCE: THE COOPERATION IN THE MANAGEMENT
OF MODERATE TO SEVERE PSORIASIS
M. Ionescu, S. Dahan, X. Bouissou, D. Interligator, B. Haliloua, L. Sulimovic on behalf of Groupe d’expertise et de réflexion sur les dermatoses inflammatoires
chroniques (GERDIC) (France)
P 070 USE OF INFLIXIMAB IN PSORIASIS VULGARIS
G. Duweb, O. Bogrein, A. Gargoom, I. Elmangush, I. Almukahal (Libyan Arab Jamahiriya)
P 071 EFFICACY AND SAFETY RESULTS OF ABT-874 VERSUS ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE CHRONIC
PLAQUE PSORIASIS
A. Menter, A. Gottlieb, C. Leonardi, F. Kerdel, S. Yoo, Y. Gu, J. Valdes (United States)
P 072 PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: ONE YEAR AFTER EMEA RECOMMENDATION OF EFALIZUMAB
SUSPENSION
M. Talamonti, A. Costanzo, M. Teoli, S. Chimenti (Italy)
P 073 GENERALIZED PUSTULAR PSORIASIS IN AN INFANT
J. Zribi and M. Mseddi, S. Marrekchi, W. Abdelmaksoud, N. Elleuch, T.J. Meziou, S. Boudaya, H. Turki (Tunisia)
P 074 CHILDHOOD PSORIASIS: A STUDY OF 110 CASES
M. Amouri, R. Ben Salah, F. Maazoun, T. Meziou, A. Masmoudi, M. Mseddi, S. Boudaya, H. Turki (Tunisia)
P 075 PHOTOTHERAPY AND PHOTOCHEMOTHERAPY IN CHILDREN – OUR EXPERIENCE
R. Ceovic, A. Pasic, J. Lipozencic, K. Kostovic, S. Murat Susic, M. Skerlev, K. Husar (Croatia)
P 076 SEVERE PSORIASIS IN CHILDREN: A REPORT OF 13 CASES
A. Sellami, H. Zribi, A. Mbazaa, I. Zaraa, R. Cheikrouhou, S. Trojett, D. El Euch, M. Mokni, A. Ben Osmen (Tunisia)
P 077 FACIAL PSORIASIS IN CHILDREN – TREATMENT MODALITIES
R. Ceovic, A. Basta Juzbasic, A. Pasic, K. Kostovic, S. Murat Susic, J. Lipozencic (Croatia)
P 078 PSORIASIS IN CHILDHOOD: STUDY OF 127 CASES
R. Benmously, H. Hammami, T. Badri, S. Ben Jennet, H. Marrak, S. Fenniche, I. Mokhtar (Tunisia)
P 079 PSORIASI VULGARIS IN AN INFANT BORNE AFTER GRAVIDIC CHOLESTASIS
A. Salhi and the Algerian Society of Dermatology (Algeria)
P 080 CHILDHOOD PSORIASIS. EPIDEMIOLOGICAL AND CLINICAL STUDY ABOUT 240 TUNISIAN PATIENTS
A. Khaled, I. Belghith, M. Ben Hamida, F. Zeglaoui, B. Fazaa, M. Kharfi, M. R. Kamoun (Tunisia)
P 081 INFANTILE PSORIASIS: A RETROSPECTIVE STUDY OVER 10 YEARS
N. Kerkeni, R. Benmously Mlika, S. Ben Jennet, T. Badri, H. Marrak, S. Fenniche, I. Mokhtar (Tunisia)
P 082 PEDIATRIC PSORIASIS: CLINICAL AND GENETIC COMPARISON TO ADULT PSORIASIS
S. Vogel, W. Liao, R. Rajaii, K. Cordoro (United States)
P 083 EFFECTIVENESS ANALYSIS OF TOPICAL PREPARATIONS CONTAINIG HYDROXYACIDS IN TREATMENT OF PSORIASIS OF THE SCALP
N. Rudych, T. Loskutova, A. Shevtchouk (Russian Federation)
P 084 QUESTIONNAIRE INVESTIGATION OF PREFERENCES AND SATISFACTION ABOUT TOPICAL CALCIPOTRIOL OINTMENT
N. I. Kim, J. H. Lee, K. J. Kim, J. I. Youn, Y. B. Choe, K. J. Ahn, J. H. Choi, T. Y. Kim (Republic of Korea)
P 085 QUESTIONNAIRE INVESTIGATION OF PREFERENCES AND SATISFACTION ABOUT TOPICAL MODALITIES FOR THE TREATMENT OF
SCALP PSORIASIS
H. J. Song, T. Y. Kim, N. I. KIm, Y. B. Choe, C. C. Park, J. H. Choi, K. J. Kim (Republic of Korea)
P 086 USEFULNESS OF THE FORMULA CLOBETASOL 0.05%, ACETYLSALICYLIC ACID 6% AND PROPYLENE GLYCOL FOR THE TREATMENT OF
PALMOPLANTAR PSORIASIS
J. M. Fernández Vozmediano, C. Carranza Romero, J. C. Armario Hita (Spain)
P 087 LOW-DOSE SHORT-TERM CICLOSPORIN (NEORAL®) THERAPY IS EFFECTIVE FOR PSORIASIS PATIENTS AND IMPROVED PATIENTS’
QUALITY OF LIFE ASSESSED BY SKINDEX-16 AND GHQ-28
Y. Okubo, S. Natsume, K. Usui, R. Tsuboi (Japan)
P 088 SAFETY OF METHOTREXATE IN PSORIASIS
M. Amouri, F. Maazoun, R. Ben Salah, M. Mseddi, S. Boudaya, H. Turki (Tunisia)
P 089 METHOTREXATE IN THE TREATMENT OF SEVERE PSORIASIS: A TUNISIAN STUDY
A. Khaled, M. Ben Hamida, I. Belghith, D. Baccouche, F. Zeglaoui, B. Fazaa, M. Kharfi, M. R. Kamoun (Tunisia)
P 090 OPTIONS AND THERAPY LIMITS IN A CASE OF SEVERE PSORIASIS
D. Branisteanu, G. Mihaila, A. Alupoaei, E. Ciubotariu, M. Cherciu, D. Branisteanu (Romania)
P 091 NEUTROPHILIC INFLAMMATION INHIBITORS IN TREATMENT OF PUSTULAR PSORIASIS
K. Jaber, S. Youssef, A. Souissi, S. Ben Taazayet, A. Ben Mna, M. R. Dhaoui, N. Doss (Tunisia)
P 092 METHOTREXATE: SIDE EFFECTS THROUGH A PHARMACOVIGILANCE CENTER ANALYSIS
A. Ben Mna, S. Youssef, K. Jaber, A. Souissi, S. Ben Taazayet, M. R. Dhaoui, N. Doss (Tunisia)
P 093 REPUVA – INDIAN EXPERIENCE – MAXIMUM BENEFIT WITH MINIMUM EFFECTIVE THERAPY
S. Gurnurkar, A. Kumar, M. Basheeruddin (India)
P 094 SEVERE FOLLICULITIS IN PATIENT ON ADALIMUMAB FOR CHRONIC PLAQUE PSORIASIS AND PSORIASIS ARTHRITIS
B. Gasior-Chrzan (Norway)
P 095 ETANERCEPT - AN INDIAN EXPERIENCE (A STUDY OF 40 CASES)
A. Kumar, A. Parthasaradhy (India)
P 096 FASTER RESPONSE AND BETTER TOLERABILITY OF FUMARIC ACID ESTERS IN TREATING PLAQUE-PSORIASIS USING A MODIFIED
DOSING REGIME
F. Bachmann, G. Kokolakis, W. Sterry, S. Philipp (Germany)
P 097 CHOLESTATIC HEPATITIS IN GENERALIZED PUSTULAR PSORIASIS
S. Ben Taazayet, K. Jaber, S. Youssef, A. Ben Mna, A. Souissi, M. R. Dhaoui, N. Doss (Tunisia)
P 098 MÉTHOTREXATE-INDUCED INTERSTITIAL LUNG DISEASE IN AN ARTHROPATIC PSORIASIS PATIENT
A. Ben Mna, K. Jaber, S. Youssef, S. Ben Taazayet, A. Souissi, M. R. Dhaoui, N. Doss (Tunisia)
P 099 FOLLOW-UP OF PATIENTS SUFFERING FROM PSORIASIS TREATED WITH EFALIZUMAB AFTER WITHDRAWAL OF THE DRUG FROM THE
MARKET
S. Urbancek, J. Pec, J. Sevc, K. Martinaskova, K. Martinaskova (Slovakia)
P 100 DIFFERENT NARROW BAND-UVB DOSAGE REGIMENS IN DARK SKINNED PSORIATICS: A PRELIMINARY STUDY
H. Mashaly, M. El Mofty, R. Youssef, D. Mahgoub, E. El-Nabarawy, N. Sameer (Egypt)
P 101 OUR NEW DEVISED METHOD DETERMINING THE INTIAL DOSE OF NARROW-BAND UVB TREATMENT WITH COLORIMETRIC L* VALUE
J. I. Youn, I. H. Kwon, H. H. Kwon (Republic of Korea)
P 102 ETANERCEPT PLUS NARROWBAND UVB PHOTOTHERAPY IS SUPERIOR TO ETANERCEPT MONOTHERAPY OF PSORIASIS
T. Gambichler, A. Kreuter, N. Scola, C. Tigges, M. Skrygan (Germany)
P 103 LYSOZYME AND IMMUNOGLOBULINE A CONCENTRATION IN SALIVA OF PSORIASIS PATIENTS TREATED WITH UVB AND PUVA
B. Gasior-Chrzan (Norway)
P 104 A LARGE SCALE ANALYTICAL STUDY ON EFFICACY OF DIFFERENT PHOTO(CHEMO)THERAPEUTIC MODALITIES IN THE TREATMENT OF
PSORIASIS
M. El Mofty, W. Mostafa, M. Bosseila, R. Youssef, S. Essmat, A. El Ramly, M. Fawzi, D. Mahgoub, N. Nagui, M. El-Fangary, M. Fathy, H. Mashaly
(Egypt)
P 105 A COMPARATIVE STUDY OF DIFFERENT TREATMENT FREQUENCIES OF PSORALEN AND ULTRAVIOLET A IN PSORIATIC PATIENTS WITH
DARKER SKIN TYPES (RANDOMIZED CONTROLLED STUDY)
H. Mashaly, M. El Mofty, H. El-Weshahy, R. Youssef, M. Abdel-Halim, M. El Hawary (Egypt)
P 106 TOPICAL THERAPY INFLUENCE ON PSYCHIC AND EMOTIONAL STATE OF PATIENTS WITH PSORIASIS
I. Korsunskaya and Z. Niewozinska, I. Danilin, L. Togoeva, O. Dordzieva, E. Lukyanova, M. Minnibaev (Russian Federation)
P 107 PSORIATIC ARTHRITIS: TEMPOROMANDIBULAR JOINT INVOLVEMENT AS THE FIRST ARTICULAR PHENOMENON
U. Garagiola, C. Bellintani, V. Carletti, P. Cressoni, G. Farronato (Italy)
P 108 ULTRASONOGRAPHIC FINDINGS IN PATIENTS WITH CHRONIC PLAQUE-TYPE PSORIASIS WITHOUT MUSCULOSKELETAL CLINICAL
INVOLVEMENT
E. Dauden, I. Moller, E. De-Miguel, E. Batlle-Gualda, C. Acebes, E. Brito, L. Mayordomo, C. Moragues, J. Uson, J. De-Agustin, A. Martinez, E. Rejon,
A. Rodriguez, E. Naredo (Spain)
P 109 PSORIATIC ARTHRITIS: SEVERITY ASSESSMENT
S. Gusis and N. Fara, K. Mendoza, F. Montoya, A. Castelli, E. Kerzberg, N. Kogan, R. Veira, A. Crespo (Argentina)
P 110 PSORIATIC ARTHRITIS IN A CHILD WITH TEMPORO-MANDIBULAR JOINT INVOLVEMENT
R. Meghrabi, F. Ait Belkacem, N. Lassal, M. Khouazem, I. Benkaidali (Algeria)
P 111 BLASCHKO-LINEAR PSORIASIS WITH ACUTE RHEUMATIC FEVER: AN ASSOCIATION TO DISCUSS?
M. T. Jalel and T. Zaz, M. Mseddi, S. Boudaya, H. Turki (Tunisia)
P 112 PSORIATIC ARTHRITIS: DISPOSITION, CONSTITUTIVE AND PROVOKING FACTORS IN 50 PATIENTS
R. Schopf, M. Asefi (Germany)
P 113 CONDYLAR AND MANDIBULAR MORPHOLOGIC AND VOLUMETRIC CHANGES IN PSORIATIC ARTHRITIS
U. Garagiola, V. Carletti, C. Bellintani, L. Mercatali, G. Farronato (Italy)
P 114 RELATIONSHIPS BETWEEN THE INCIDENCE OF ONYCHOMYCOSIS AND NAILS PSORIASIS
S. Valiukeviciene, S. Kavaliauskiene, R. Povilionyte, J. Jakubovskiene, D. Jasaitiene, R. Petrauskiene, R. Zarankiene, E. Skrodeniene,
A. Vitkauskiene (Lithuania)
P 115 METABOLIC SYNDROME IN JAPANESE PSORIASIS PATIENTS – CORRELATIONS WITH DISEASE SEVERITIES AND THE INFLUENCE OF
TREATMENTS
T. Ito, O. Fukuchi, H. Katayama, N. Takagi, S. Kikuchi, H. Nakagawa, R. Yoshihara (Japan)
P 116 PSORIASIS AND METABOLIC SYNDROME; PRELIMINARY STUDY: EXPERIENCE IN THE DEPARTMENT OF DERMATOLOGY OF TELMCEN
(WEST ALGERIA)
O. Boudghene Stambouli, B. Dahmani (Algeria)
P 117 WEIGHT GAIN ASSOCIATED WITH ANTI-TNF? IN PSORIASIS: A NEGLECTED SIDE EFFECT?
N. Bonnet, A. Nuccio-Lévèque, M. Koeppel, P. Berbis (France)
P 118 PSORIASIS AND ATOPIC DERMATITIS-ARE THEY MUTUALLY EXCLUSIVE?
N. Kondapally, A. Kumar, T. Aziz (India)
P 119 ASSESSMENT OF THE ATHEROGENIC PROFILE OF LIPIDS AND LIPOPROTEIN AND THEIR RELATIONSHIP WITH SEVERITY OF PSORIASIS
M. El Asmi, A. Mebazaa, W. Zidi, Y. Zayani, R. Cheikhrouhou, S. Ounifi, T. Hdider, M. Fkih, M. Mokni, A. Ben Osman, N. Kaabachi (Tunisia)
P 120 PHOTOSENSITIVITY IN PATIENTS OF PSORIASIS – THE UNFORTUNATE FEW
S. Gurnurkar, A. Kumar (India)
P 121 PSORIASIS AND ATOPIC DERMATITIS-ARE THEY MUTUALLY EXCLUSIVE?
N. Kondapally, A. Kumar, T. Aziz (India)
P 122 FEATURES OF CLINICAL COURSE OF PSORIASIS ON THE BACKGROUND OF THE METABOLIC SYNDROME AS A RESULT OF
RETROSPECTIVE ANALYSIS
M. Kozlova (Ukraine)
P 123 CARDIOVASCULAR PATHOLOGY IN PATIENTS WITH PSORIASIS: RISK AND REALITIES
M. Kozlova (Ukraine)
P 124 META-ANALYSIS: PSORIASIS AND BMI
V. Espinoza-Chavez (Mexico)
P 125 QUESTIONNAIRE-BASED SURVEY OF THE TREATMENT OF PSORIASIS PATIENTS WITH HEPATITIS C IN JAPAN
S. Imafuku, J. Nakayama (Japan)
P 126 AUTOIMMUNE PHENOMENA DURING LONG-TERM ANTI-TNF TREATMENT FOR PSORIASIS: EFFECT ON THE PSORIASIS AREA AND
SEVERITY INDEX
R. Schopf, N. Sapyega (Germany)
P 127 DO PSORIATIC PATIENTS HAVE HIGHER PROPORTIONS OF METABOLIC SYNDROME AND ITS COMPONENTS IN COMPARISON WITH
CONTROLS AND PATIENTS WITH INFLAMMATORY DERMATOSIS OTHER THAN PSORIASIS?
A. Mebazaa, M. El Asmi, W. Zidi, R. Cheikhrouhou, Y. Zayani, F. Kanoun, D. El Euch, M. Mokni, H. Slimane, N. Kaabechi, A. Ben Osman (Tunisia)
P 128 RELATIONSHIP BETWEEN BMI AND PSORIASIS SEVERITY OF PSORIASIS BRAZILIAN CENTER PATIENTS
C. Sabbag, M. Solis (Brazil)
P 129 PSORIASIS AND CARDIOVASCULAR RISK FACTORS - A CASE CONTROL STUDY ON INPATIENTS
J. Shapiro, A. Cohen, R. Tal, D. Witsman, M. David (Israel)
P 130 THE PREVALENCE OF METABOLIC SYNDROME IN PSORIASIS PATIENTS IN A LEBANESE POPULATION
S. Itani, A. Arabi, A. Kibbi (Lebanon)
P 131 A STUDY OF CO- MORBID CONDITIONS IN PSORIASIS
J. Thomas (India)
P 132 OBESITY, DIABETES MELLITUS, HYPERTENSION AND SMOKING: HIDDEN CULPRITS IN CAUSING PSORIASIS
R. Batra (India)
P 133 THE ROLE OF DRUGS IN THE INDUCTION AND/OR EXACERBATION OF PSORIASIS
K. H. Basavaraj (India)
P 134 THE ASSOCIATION BETWEEN PSORIASIS, DIABETES MELLITUS, HYPERTENSION AND OBESITY IN INDIA
T. Aziz, A. Kumar, M. B (India)
P 135 COMORBIDITY AND PSORIASIS
C. Carranza Romero, J. M. Fernández Vozmediano, J. C. Armario Hita (Spain)
P 136 ASSOCIATION OF PSORIASIS AND OBSTRUCTIVE SLEEP APNEA-HYPOPNEA SYNDROME: A HOSPITAL- BASED PILOT STUDY OF 15
PSORIATIC PATIENTS WHO UNDERWENT POLYSOMNOGRAPHY
E. Papadavid, K. Vlami, D. Sgouros, C. Bamia, S. Giatrakou, S. Gyftopoulos, H. Boutati, S. Papiris, N. Stavrianeas (Greece)
P 137 COMPARISON OF QUALITY OF LIFE BEFORE AND AFTER TREATMENT IN PSORIASIS PATIENTS
K. Kim, B. Kim, S. Park (Republic of Korea)
P 138 STUDY OF EMOTIONAL STRESS, ALCOHOL AND TOBACCO ASSOCIATED TO BENIGN MIGRATORY GLOSSITIS AND CUTANEOUS
PSORIASIS
H. Gonzaga, M. Chaves, M. Jorge, J. Tomimori, C. Barbosa (Brazil)
P 139 MENTAL AND EMOTIONAL STATE OF PATIENTS WITH GENERALIZED PSORIASIS
I. Korsunskaya and Z. Niewozinska, I. Danilin, L. Togoeva, O. Dordzieva, E. Lukyanova, M. Minnibaev (Russian Federation)
P 140 SOME PSYCHOLOGICAL CHARACTERISTICS OF PATIENTS SUFFERING FROM PSORIASIS
T. Zarkovic Palijan, G. Krnjevic-Pezic (Croatia)
P 141 EFFICACY OF COUNSELLING IN THE MANAGEMENT OF PSORIASIS
C. Kumar (India)
P 142 QUALITY OF LIFE INDEX OF PSORIASIS IN LIBYAN PATIENTS
G. Duweb, B. Salama (Libyan Arab Jamahiriya)
P 143 PATIENT PREFERENCES FOR PROCESS AND OUTCOME ATTRIBUTES IN PSORIASIS TREATMENT: RESULTS FROM A PILOT STUDY WITHIN
A GERMAN UNIVERSITY HOSPITAL OUTPATIENT CLINIC
M. Schaarschmidt, A. Schmieder, N. Umar, D. Terris, M. Goebeler, W. Peitsch (Germany)
P 144 BRAZILIAN SURVEY WITH PATIENTS WITH PSORIASIS
C. Sabbag (Brazil)
P 145 EXPRESSION OF HLA-G TARGETS PRIMARIALY AFFECTED SKIN IN PSORIASIS PATIENTS
R. Cardili, C. Souza, E. Donadi, E. Soares, C. Soares (Brazil)
P 146 DOCETAXEL INDUCED PSORIASIS
D. Kerob, C. Le Maignan, M. Vignon-Pennamen, C. Lebbe (France)
P 147 INTERLEUKIN-6 COUNTERACTS THE EFFECTS OF CYCLOSPORIN A ON EXTRACELLULAR MATRIX METABOLISM BY HUMAN DERMAL
FIBROBLASTS
M. Abe, Y. Yokoyama, O. Ishikawa (Japan)
P 148 THE EXPRESSION OF TH-17 RELATED CYTOKINES IN PSORIATIC PLAQUE
Y. B. Choe, K. J. Ahn, C. C. Park, J. H. Choi, J. I. Youn, N. I. Kim (Republic of Korea)
P 149 CHANGES OF EGF SERUM CONCENTRATION DURING IN PSORIASIS DISEASE COURSE
I. Hartmane, I. Ivdra, I. Mikazans and Iveta Ivdra Ilona Hartmane Ingmars Mikazans (Latvia)
P 150 INAUGURAL GENERALIZED PUSTULAR PSORIASIS TRIGGERED BY TYPHOID FEVER
A. Mebazaa, R. Cheikhrouhou, H. Moula, S. Abdelatif, S. Trojjet, H. Zribi, I. Zaraa, D. El Euch, M. Mokni, M. Lakhal, A. Ben Osman (Tunisia)
P 151 NF-KB CUTANEOUS EXPRESSION UNDER CYCLOSPORINE EFFECT IN PATIENTS WITH PSORIASIS PLAQUES
S. Carneiro, M. da Silva, F. Soares, M. Ramos-e-Silva, J. M. Cunha (Brazil)
P 152 RETENTION OF PALMAR DERMATOGLYPHIC PATTERN IN NON-PSORIATIC DERMATOSES – A USEFUL CLINICAL SIGN?
J. Thomas (India)
P 153 PSORIASIS NEW TREATMENT
M. Amer (Egypt)
P 154 BIOCHEMICAL HOMEOSTASIS IN PSORIASIS:DIAGNOSTIC AND THERAPEUTIC POTENTIAL
K. H. Basavaraj (India)
P 155 BASIC PATHOGENIC MECHANISMS OF PSORIASIS
A. Rakhmatov, R. Keshileva, D. Rakhmatova, N. Mirkhamidova (Uzbekistan)
P 156 NEUROPEPTIDES AND THEIR RECEPTORS IN PSORIATIC SKIN IN RELATION TO PRURITUS
J. Choi (Republic of Korea)
P 157 PRODUCTION OF IL-8 BY CIRCULANT CLA+ T CELL LYMPHOCYTES WITH SKIN TROPISM IN PSORIASIS AND HEALTHY CONTROLS
M. Ferran, A. Galvan, A. Gimenez-Arnau, R. Pujol, L. Santamaria (Spain)
P 158 INHIBITION OF INTERLEUKIN 23-INDUCED UP-REGULATION OF KERATIN 17 AS A PUTATIVE PSORIASIS AUTO-ANTIGEN BY
1,25-DI-HYDROXY-VITAMIN D3 IN VITRO
R. Böckelmann, H. Gollnick, B. Bonnekoh (Germany)
P 159 APOPTOSIS IN PSORIASIS
G. Kokolakis, J. Eberle, A. Tosca, W. Sterry, S. Philipp, S. Krüger-Krasagakis (Germany)
P 160 COMPARISON OF THE EXPRESSION PROFILE OF JUNB, C-JUN, AND S100A8 (CALGRANULIN A) IN PSORIASIS VULGARIS AND
GUTTATE PSORIASIS
C. C. Park, Y. B. Choe, H. J. Song, J. H. Choi, N. I. Kim (Republic of Korea)
P 161 AN INVESTIGATION OF ANTI-LEISHMANIA MAJOR AND ANTI-HYDATID CYST SPECIFIC ANTIBODIES IN PSORIASIS
Y. Galaï, S. Samoud, S. Saadi, L. Lachheb, M. Denguezli, R. Nouira (Tunisia)
P 162 CHIKUNGUNYA INFECTION, A NEW PROVOCATING FACTOR FOR PSORIASIS
K. Seetharam, K. Sridevi (India)
P 163 HIGH DETECTION OF HUMAN PARVOVIRUS B19 DNA IN PSORIATIC LESIONS
S. Samoud, Y. Galai, N. Hannachi, R. Ben Asker, L. Boussouffara, M. Denguezli, R. Nouira, H. Louzir (Tunisia)
P 164 HIGH EXPRESSION OF CYTOLYTIC PROTEINS IN PSORIATIC LESIONS: UP REGULATION WITH DISEASE ACTIVITY AND CONCOMITANT
MICROBIAL INFECTION
S. Samoud, Y. Galai, N. Hannachi, M. Denguezli, R. Nouira, H. Louzir (Tunisia)
P 165 PSORIASIS AND INTERNAL DISEASES
T. Leonidze, K. Shvelidze (Georgia)
P 166 PDL-ND:YAG LASER IN THE TREATMENT OF NAIL PSORIASIS
G. Bali, L. Kemény, R. Gyulai, R. Kui, M. Gaál (Hungary)
P 167 PITYRIASIS RUBRA PILARIS OF THE ADULT TYPE I RESOLVED AFTER MONOTHERAPY WITH USTEKINUMAB
M. Bellutti, B. Bonnekoh, H. Gollnick (Germany)
P 168 LOW-INTENSITY LASER RADIATION EFFECTS ON ANTIOXIDANT STATUS IN PSORIASIS
I. Korsunskaya and R. Aleid, E.V. Kalinia, N.N. Chernov, M.M. Nurmuradov, A.N. Saprin, M.T. Minnibaev, D.N. Serov (Russian Federation)
P 169 TREATMENT OF PLAQUE-TYPE PSORIASIS WITH ORAL CF101: DATA FROM AN EXPLORATORY PHASE 2 CLINICAL TRIAL
M. David, L. Akerman, M. Ziv, M. Kadurina, D. Gospodinov, F. P. Pavlotsky, R. Yankova, V. Kouzeva, M. Ramon, O. Katz, M. Kerner, A. Zoabi,
B. Dimitrov, N. Ivanov, M. Ralinovska, V. Pavlova-Petkova, H. Trau, G. Kriger, F. Salameh, M. Gyurova, M. Hitova, A. Dancheva-Atanasova,
P. Kaliasheva-Zaimova, A. Mercer, S. Fishman, Z. Harpaz, M. Farbstein, S. Bar Yehuda, M. Sikverman, W. Kerns, D. Bristol, D. Bristol, I. Cojn,
P. Fishman (Israel)
P 170 THE CHANGES IN EXPRESSION OF ICAM-3, KI-67, AND CD31 IN PSORIATIC LESIONS BEFORE AND AFTER ETANERCEPT TREATMENT
U. Tursen, B. Tursen, A. Bahali, D. Apa (Turkey)
P 171 PSORIATOR
J. Aldana, G. Roman and Giovanna Elizabeth Roman (Colombia)
P 172 TOPICAL AMMONIUM-TRICHLOROTELLURATE (AS101) IN THE TREATMENT OF MILD PLAQUE- TYPE PSORIASIS; CORRELATION BETWEEN
CLINICAL IMPROVEMENT AND CHANGES IN INFLAMMATORY CYTOKINES
L. Akerman, B. Sredni, M. Albek, M. David (Israel)
P 173 DOCETAXEL INDUCED PSORIASIS
D. Kerob (France)
P 174 4 CASES OF ANNULAR PSORIASIS
O. Fukuchi, H. Nakagawa (Japan)
P 175 HERITABILITY TO CUTANEOUS PSORIASIS AND BENIGN MIGRATORY GLOSSITIS THROUGH THE STUDY OF FAMILY GENEALOGY OF
THESE DISEASES HOLDERS
H. Gonzaga, M. Chaves, M. Jorge, J. Tomimori (Brazil)
P 176 SUCCESSFUL USE OF ADALIMUMAB (HUMIRA®) IN PITYRIASIS RUBRA PILARIS
A. Palacios, R. González, N. Agesta, E. Acebo, L. Díaz-Ramón, J. Gardeazabal (Spain)
P 177 DIFFERENT TYPES OF DRUG EXPOSURE IN PATIENTS WITH PSORIASIS
H. Ansarin, R. Jarvand, M. Ardalan, S. Meysami (Islamic Republic of Iran)
P 178 FAMILIAL CHILDHOOD PUSTULAR PSORIASIS
J. Zribi and Mseddi M, S. Marrekchi, N. Elleuch, A. Masmoudi, T.J. Meziou, S. Boudaya, H. Turki (Tunisia)
P 179 ONYCHODYSTROPHY IN PATIENTS WITH VARIOUS FORMS OF PSORIASIS
U. Adaskevich, V. Zykava (Belarus)
P 180 BRONCHOSPASM IN A PSORIASIS PATIENT UNDER TREATMENT WITH ETANERCEPT
T. Torres, S. Vilaça, G. Velho, M. Selores (Portugal)
P 181 CAN PSORIASIS START AS LICHENPLANUS ?
K. Seetharam, P. Vidyasagar, K. Sridevi (India)
P 182 CHARACTERIZATION OF 500 PATIENTS WITH PSORIASIS IN CHILE
W. Romero, M. Inostroza, M. Daziano, C. de la Cruz (Chile)
P 183 PHOTOSENSITIVE PSORIASIS
S. Youssef, S. Ben taazayet, K. Jaber, A. Ben Mna, A. Souissi, M. R. Dhaoui, N. Doss (Tunisia)
P 184 PSORIASIS AND HIV: REPORT OF 2 CASES AND REVIEW OF THE LITERATURE
A. Mebazaa, A. Hawilo, R. Abelmalek, R. Cheikhrouhou, S. Trojjet, H. Zribi, I. Zaraa, D. El Euch, M. Mokni, F. Ben Chaabene, A. Ben Osman (Tunisia)
P 185 SYSTEMIC LUPUS ERYTHEMATOSUS AND PSORIASIS: A RARE COMBINATION
B. Ben Dhaou, F. Boussema, R. Ben Mously, S. Ketari, H. Marrak, O. Cherif, I. Mokhtar, L. Rokbani (Tunisia)
P 186 EPIDEMIO-CLINICAL STUDY OF PSORIASIS IN TUNISIA: RESULTS OF A MULTICENTRIC RECRUITMENT
S. Youssef, K. Jaber, A. Khaled, M. Zghal, M. Denguezli, J. Meziou, M. R. Dhaoui, M. R. Kamoun, I. Mokhtar, R. Nouira, H. Turki, N. Doss (Tunisia)
P 187 EPIDEMIOLOGIC, CLINICAL AND THERAPEUTICAL ASPECTS OF PSORIASIS AT DAKAR
F. Ly, M. Ndiaye, M. Diallo, M. T. Dieng, A. Diop, A. Kane, O. Niang, B. Ndiaye (Senegal)
P 188 LYMPHOPROLIFERATIVE DISORDER IN A PSORIATIC TREATED WITH METHOTREXATE
M. Amouri, R. Ben Salah, S. Boudaya, M. Mseddi, T. Meziou, A. Masmoudi, H. Turki (Tunisia)
P 189 EVALUATION OF ERYTHROCYTE CHANGES IN PORTUGUESE PSORIATIC PATIENTS - RELATION WITH TREATMENT
S. Coimbra, H. Oliveira, F. Reis, L. Belo, S. Rocha, A. Figueiredo, F. Teixeira, E. Castro, P. Rocha-Pereira, A. Santos-Silva (Portugal)
P 190 CLINICAL PROFILE OF PSORIASIS IN YEMEN, A 4 YEARS RETROSPECTIVE STUDY OF 241 PATIENTS
M. Alshami (Yemen)
P 191 DRUG-INDUCED PSORIASIS
S. Tinawi (Syrian Arab Republic)
P 192 ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS IN A PATIENT WITH PALMOPLANTAR PUSTULOSIS AND PSORIASIS IN PLAQUES
M. Rodríguez-Vázquez, J. M. Azaña-Defez, M. L. Martínez-Martínez, J. M. Pardal-Fernández, L. Iñiguez (Spain)
P 193 RARE DRUG-ERUPTION AFTER ADALIMUMAB
P. Ponholzer (Austria)
P 194 NEUTROPHILIC CHOLANGITIS DURING GENERALIZED PUSTULAR PSORIASIS
R. Meghrabi, F. Ait Belkacem, N. Lassal, N. Ben Mhidi, M. Khouazem, I. Benkaidali (Algeria)
P 195 PSORIASIS: EPIDEMIOLOGICAL STUDY OF 97 CASES IN 3 CLINICS
H. Hammadi, S. Zobiri, H. Sahel (Algeria)
P 196 PSORIASIS AS A SIDE EFFECT OF INFLIXIMAB: A CASE REPORT
I. Fernandes, T. Torres, M. Sanches, P. Lago, G. Velho, M. Selores (Portugal)
P 197 ANTI-MUTATED CITRULLINATED VIMENTIN ANTIBODIES SEEMS TO BE RATHER A SEROLOGICAL MARKER OF PSORIASIS THAN OF
RHEUMATOID ARTHRITIS
S. Samoud, Y. Galai, L. Lachheb, M. Denguezli, C. Belajouza, I. Bouajina, R. Nouira, J. Boukadida (Tunisia)
P 198 PSORIASIS EPIDEMIOLOGY IN UZBEKISTAN
A. Rakhmatov, D. Rakhmatova, N. Mirkhamidova (Uzbekistan)